About

Matthew Rutledge

Matthew Rutledge is President and Co-Founder of MD Labs and has an active role in the development and implementation of Rxight.  Matthew has a diverse background in the medical field that began with his Pre-medical education, learning laboratory operations as an undergrad, caring for patients as a hospital volunteer, working alongside physicians and providers as a medical device sales consultant, and now as a laboratory Owner.  The experience of seeing how ADRs and ineffective medications affect patient outcomes has been the driving force behind Matthew’s enthusiasm for pharmacogenetics and Rxight.  After hearing from numerous healthcare providers about how curious it can be to see patients prescribed the same medications in the same dosing have very different outcomes.  With this in mind, Matthew spearheaded the MD Labs R&D team to develop Rxight to offer patients this precision medicine solution.  Matthew is a member of CPIC's implementation group, the PGRN, and IGNITE research programs and continues to stay on top of all of the latest news and updates that pertain to pharmacogenetics in order to make Rxight the most robust pharmacogenetic test offering in the market.